General Biologicals Corporation

General Biologicals Corporation is a biotechnology and healthcare company specializing in the design, development, and manufacturing of in-vitro diagnostics, medical technologies, and biopharmaceuticals. Founded in 1984 as part of Taiwan’s national Hepatitis Prevention and Vaccine Program, the company pioneered Hepatitis B diagnostic kits in the market and has since expanded to a portfolio exceeding 80 products distributed across more than 40 countries. Its primary focus is on precision diagnostics, supplying hospitals, clinics, and laboratories with integrated diagnostic devices and reagents for infectious diseases, oncology, reproductive health, and personalized healthcare. General Biologicals Corporation employs advanced technology platforms, including chemiluminescent immunoassay systems and AI-driven liquid biopsy solutions, enabling precise disease detection and monitoring. Beyond diagnostics, the company’s activities cover the development of protein-based therapeutics and antimicrobial peptides for pharmaceutical, cosmetic, and oral health applications. By combining research, manufacturing, and global distribution, General Biologicals Corporation plays a significant role in advancing innovative healthcare solutions within the biotechnology sector, continually expanding its market reach in Asia and beyond.